Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Somatropin (recombinant human growth hormone) Clear all
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 10, 2026, 1:43 PM EDT
Not listed Phase 1Phase 2 Interventional

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

NCT02179255
View directory record Official record
Conditions
Female Infertility Due to Diminished Ovarian Reserve
Interventions
Human Growth Hormone, Follicle Stimulating Hormone
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

NCT00957671
View directory record Official record
Conditions
Growth Hormone Deficiency, Traumatic Brain Injury
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 10, 2026, 1:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

NCT00684957
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Recombinant Human Growth Hormone, Recombinant Human IGF-1
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 10, 2026, 1:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Muscle Effects of GH in Boys

NCT04020913
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
Somatropin injection
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy

NCT03554265
View directory record Official record
Conditions
Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
Interventions
Somatropin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 10, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional

Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease

NCT00194961
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Oct 10, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional Results available

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
Saizen®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
US Medical Information, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 10, 2026, 1:43 PM EDT
Withdrawn Not applicable Interventional

Growth Hormone for Osteoporosis Pseudoglioma Syndrome

NCT01614171
View directory record Official record
Conditions
Osteoporosis Pseudoglioma Syndrome
Interventions
Human recombinant growth hormone
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 10, 2026, 1:43 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Versartis International Trial in Adults With Long-Acting Growth Hormone

NCT02526420
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
23 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Escondido, California • Laguna Hills, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Treatment With rhIGF-1 in GHIS

NCT00571727
View directory record Official record
Conditions
Growth Hormone Insensitivity Syndrome
Interventions
mecasermin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 21 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2011
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 10, 2026, 1:43 PM EDT
Suspended Phase 4 Interventional

Effect of Cytokines on Growth of Children With Chronic Kidney Failure

NCT00194883
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

NCT00183040
View directory record Official record
Conditions
Sarcopenia, Muscle Weakness, Frailty
Interventions
Topical testosterone, Recombinant human growth hormone
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 90 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Oct 10, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

NCT04867317
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions
Somatropin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 10, 2026, 1:43 PM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

NCT00352287
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2006 · Synced Oct 10, 2026, 1:43 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Recombinant human growth hormone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
23 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 10, 2026, 1:43 PM EDT
Not listed No phase listed Observational

Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight

NCT00120497
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 10, 2026, 1:43 PM EDT
Not listed Phase 3 Interventional

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 10, 2026, 1:43 PM EDT
Completed No phase listed Observational

rhGH Therapy on Hepatic Drug Metabolism

NCT00458991
View directory record Official record
Conditions
Growth Hormone Deficiency, Dwarfism
Interventions
Dextromethorphan and Caffeine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 14 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 10, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

NCT00109733
View directory record Official record
Conditions
Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism
Interventions
recombinant human growth hormone
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
13 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Orange, California • Jacksonville, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 10, 2026, 1:43 PM EDT